A recent analysis using family history weighting and co-observation classification modeling indicated that BRCA1 c.594-2A > C (IVS9-2A > C), previously described to cause exon 10 skipping (a truncating alteration), displays characteristics inconsistent with those of a high risk pathogenic BRCA1 variant. We used large-scale genetic and clinical resources from the ENIGMA, CIMBA and BCAC consortia to assess pathogenicity of c.594-2A > C. The combined odds for causality considering case-control, segregation and breast tumor pathology information was 3.23 Â 10 À8 . Our data indicate that c.594-2A > C is always in cis with c.641A > G. The spliceogenic effect of c.[594-2A > C;641A > G] was characterized using RNA analysis of human samples and splicing minigenes. As expected, c.[594-2A > C; 641A > G] caused exon 10 skipping, albeit not due to c.594-2A > C impairing the acceptor site but rather by c.641A > G modifying exon 10 splicing regulatory element(s). Multiple blood-based RNA assays indicated that the variant allele did not produce detectable levels of full-length transcripts, with a per allele BRCA1 expression profile composed of %70-80% truncating transcripts, and %20-30% of in-frame D9,10 transcripts predicted to encode a BRCA1 protein with tumor suppression function. We confirm that BRCA1c.[594-2A > C;641A > G] should not be considered a high-risk pathogenic variant. Importantly, results from our detailed mRNA analysis suggest that BRCA-associated cancer risk is likely not markedly increased for individuals who carry a truncating variant in BRCA1 exons 9 or 10, or any other BRCA1 allele that permits 20-30% of tumor suppressor function. More generally, our findings highlight the importance of assessing naturally occurring alternative splicing for clinical evaluation of variants in disease-causing genes.
Introduction
Sequence variants that alter the highly conserved intronic dinucleotides at splice donor and acceptor sites of high-risk disease predisposition genes are often assumed to be pathogenic, due to their high likelihood to alter RNA splicing. Although such variants will almost certainly lead to disruption of normal splicing patterns, the exact nature of the resulting alternate splicing patterns cannot be reliably predicted. Indeed, a standardized classification scheme recently developed for mismatch repair gene variants through consensus across multiple international sites (1) proposes that mRNA assay and/or clinical data are necessary to upgrade dinucleotide donor and acceptor variant classification from 'likely pathogenic' to 'pathogenic'.
The dinucleotide acceptor site variant BRCA1 c.594-2A > C (also known as IVS9-2A > C) has recently been reported associated with clinical characteristics inconsistent with a high risk of cancer expected for a pathogenic BRCA1 variant (2) . Previous RNA analyses of carriers of BRCA1 c.594-2A > C indicate that this variant is associated with an aberrant mRNA profile (3, 4) , including production of exon 10 deleted out-of-frame transcripts. These observations indicate that the relationship between splicing aberrations and increased risk is not straightforward, and pose the question of which measures of mRNA transcript dysregulation best reflect variant pathogenicity, considering recommendations already published by the ENIGMA Splicing Working Group (5) . We undertook a study to assess level of risk associated with BRCA1 c.594-2A > C using segregation and largescale case-control analysis, and detailed mRNA analyses correlating genotype with aberrant mRNA profiles.
Results

Genetic studies
Characteristics of BRCA1 c.594-2A > C variant carriers identified in BCAC, CIMBA and ENIGMA are detailed in Supplementary Material, Tables S1 and S2. BRCA1 c.594-2A > C (rs80358033) was identified in 7/24 605 invasive breast cancer cases and 9/25 836 controls, when including only the 11 studies with at least one observation (Supplementary Material, Table S1 [TQ1]). Standard case-control analysis yielded an odds ratio (OR) of 0.82 (95% CI 0.26-2.47), which was little different after adjustment for principle components (OR 0.83, 95% CI 0.41-2.24). However, some studies indicated that they had performed BRCA1/2 mutation screening of cases and may have excluded cases with pathogenic variants. Since BRCA1 c.594-2A > C has generally been assumed to be pathogenic on the basis of its location at a splice acceptor site, this could create a bias due to preferential exclusion of c.594-2A > C carriers cases but not controls. After exclusion of four studies that did such genetic testing, we were left with 5/20 992 cases and 6/22 332 controls that carried the c.594-2A > C variant (see Supplementary Material, Table S1 ), yielding a revised OR of 0.87 (95% CI 0.26-2.86) after adjustment for principle components. The odds for causality based on carrier frequency and ages at diagnosis/interview in these cases and controls was 7.3 Â 10 À5 (equating to an odds against pathogenicity of 13 770:1). The case-control findings demonstrate that the BRCA1 c.594-2A > C variant is clearly not associated with a high risk of breast cancer, and is unlikely to be associated with even a moderate ($3-to 5-fold) risk of breast cancer. There were 15 BRCA1 c.594-2A > C carrier individuals from 13 families identified in the CIMBA dataset through genotyping with the iCOGS array. It was confirmed with the submitting sites that none of these individuals carried another pathogenic variant in BRCA1, and that eight of these families overlapped with those identified via ENIGMA while the proband for another family was also recruited into BCAC. Overall, information for segregation analysis was available for 14 probands from ENIGMA/CIMBA (Supplementary Material, Table  S1 ), and breast tumor pathology information for 32 cases from ENIGMA, CIMBA or BCAC (Supplementary Material, Tables S1 and  S2 ). The combined odds for causality based on segregation analysis, assuming BRCA1 age-specific risks of breast and ovarian cancer as estimated in the large study of Antoniou et al (6) , was 0.10 (ranging from 0.02 to 6.85 for individual families). The breast tumor pathology features of variant carriers were not consistent with those found commonly for high-risk BRCA1 pathogenic variant carriers. The majority of tumors were estrogen receptor (ER) positive (25/32), and the odds for causality based on pathology information was 4.98 Â 10 À 6 (200994:1 against causality).
After contacting the submitting centres and through re-investigation of original genetic test results, the BRCA1 exonic variant rs55680408 (c.641A > G, p.Asp214Gly) was confirmed to be present in all ENIGMA/CIMBA c.594-2A > C families included in the final analysis, and another 13 c.594-2A > C carriers identified by Ambry Genetics that were excluded from analysis due to lack of relevant clinical information. Specifically, review of genetic testing data by Ambry Genetics identified a total of 20 carriers of BRCA1 c.[594-2A > C; 641A > G] from >213 000 tests, including two siblings and a mother-daughter pair; there was clear evidence that the alleles were in cis from next-generation sequencing reads, and neither allele was observed alone in 2636 unrelated parent exomes. Further, all carrier individuals from BCAC were shown to share the same BRCA1 haplotype (data not shown). Based on the haplotype and genotype information, it was assumed that all BRCA1 c.594-2A > C carriers in the BCAC dataset were also carriers of c.641A > G (p.Asp214Gly). Considering case-control, segregation and pathology information, the combined odds for causality was 3.61 Â 10 
Splicing studies
Comprehensive characterization of BRCA1 alternative splicing landscape in c.[594-2A > C; 641 a > G] carriers by capillary electrophoresis and high throughput RNA sequencing To search for a plausible biological mechanism explaining the lack of evidence for an increased cancer risk in BRCA1 c.[594-2A > C; 641A > G] carriers, we first performed a comprehensive characterization of the BRCA1 alternative splicing landscape in the vicinity of exon 10.With this aim, we performed a series of capillary electrophoresis analyses on RNAs obtained from lymphoblastoid cell lines (LCLs) (see Materials and Methods). We have shown previously that this approach is highly sensitive, allowing comprehensive identification, characterization and semiquantification of alternative splicing (4, 7) . Experiments performed with two combinations of forward and reverse primers located in exons 8 and 11 detected up to five different alternative splicing events both in LCLs from one c.[594-2A > C; 641 A > G] carrier (Carrier 1) and healthy controls (Fig. 1) , including three in-frame (full-length (FL), D9,10, and ᭢10p), and two out-of-frame (D9 and D10). All but ᭢10p (r.594-21_594-1ins) have been described previously as naturally occurring BRCA1 alternative splicing events in control samples (7) . No c.[594-2A > C; 641A > G] specific events were identified. Overall, experiments conducted in the presence of puromycin (Puroþ experiments in Fig. 1 S2C ). Incidentally, our data supports ᭢10p as a naturally occurring BRCA1 alternative splicing event not previously reported, probably due to its very low SF. Capillary electrophoresis findings (in particular the lack of variant allele-specific transcripts, and the detection of ᭢10p in Controls) were confirmed by RNAseq experiments (Supplementary Material, Fig. S3 ).
Quantitative analyses combined with alternative splicing event specific biallelic expression analyses confirms that c.[594-2A > C; 641A > G] modifies the BRCA1 alternative splicing landscape, but not the overall BRCA1 expression level The comprehensive analysis of the BRCA1 alternative splicing landscape described above did not provide an obvious explanation for why c.[594-2A > C; 641A > G] carriers do not display features of a standard pathogenic BRCA1 variant. Yet, the absence of carrier-specific transcripts prompted us to speculate that it is perhaps the actual level of naturally occurring in-frame transcripts in variant allele carriers that may explain the genetic findings, in particular levels of FL and D9,10 transcripts given that᭢10p transcript levels were very low. Since capillary electrophoresis is a semi-quantitative approach, we decided to perform further analyses with quantitative PCR (qPCR) and digital PCR (dPCR) that, overall, confirmed capillary electrophoresis findings (Fig. 2) . qPCR absolute quantification of individual alternative splicing events in Carrier 1 estimated for D9,10 SF a value of 19%60.9, in the upper-limit of Controls (ranging from 4% to 17%; Fig. 2A , left), together with an obvious reduction of FL transcripts ( Fig. 2A, right) . In addition to D9,10, three other naturally occurring in-frame alternative splicing events involving exon 10 and/or nearby exon 11 have been described, namely D9_11, D11 and D11q (7). We used qPCR absolute quantification to estimate the SF of these alternative splicing events, detecting an increase of (D9,10þD11q) transcripts, nor increases overall BRCA1expression level, but rather substitutes FL transcripts (containing exons 9 and 10) with out-of-frame D10 transcripts, such that the contribution of in-frame D9,10 transcripts to the overall expression level is similar or slightly higher (see Fig. 2 , Supplementary Material, Fig. S2 ) to that observed in wild-type (WT) alleles. Of note, according to our data the overall model is also probably true in the subset of BRCA1D11q transcripts (see Supplementary Material, Figs S2C and S4B). According to this model, BRCA1D9 (out-of-frame) and BRCA1 ᭢10p (in-frame) contribution to the overall expression level are very low both in variant and WT alleles (see Fig. 2B and C), and hence irrelevant to explain the lack of risk observed in variant allele carriers.
Splicing reporter minigene analyses reveal that c.641A > G is causing exon 10 skipping in c.[594-2A > C; 641 a > G] carriers We also performed minigene assay experiments to dissect the contribution of the individual variants c.594-2A > C and c.641A > G to the splicing pattern observed in variant allele carriers. Experiments were performed with two minigene assays (pCAS2-BRCA1-Exon10 and pB1). A schematic representation of these reporter minigenes is shown in Figure 3 (8) . pCAS2-BRCA1-Exon10 and pB1 experiments performed in HeLa cells, as well as pB1 experiments performed in breast (MCF7 and HBL100) and ovarian (IGROV-1) cell lines, revealed that both c.594-2A > C and c.641A > G impair normal exon 10 splicing, albeit with different outcomes (Fig. 3) . pCAS2-BRCA1-Exon10 c.594-2A > C and pB1 c.594-2A > C predominantly produced᭢10p transcripts, but also a minor amount of D10 transcripts (Fig. 3A) , a finding confirming previous pSPL3-BRCA1-Exon10 experiments performed in COS-7 cells (9). In contrast, pCAS2-BRCA1-Exon10 c.641A > G and pB1 c.641A > G mostly produced D10 but no detectable᭢10p. The finding that c.641A > G causes exon 10 skipping albeit being located outside the splice site, suggests that this variant disturbs the regulation of exon 10 splicing, probably by destroying splicing enhancer elements and/or by creating splicing silencer elements, a hypothesis supported by an in silico analysis based on ESRseq scores (Supplementary Material, Fig. S7A ). The presence of regulatory mechanisms full-length; D9, exon 9 skipping; D10, exon 10 skipping; D9,10, skipping of both exons 9 and 10; asterisk, retention of 21 intronic nucleotides immediately upstream exon 10 (᭢10p). One can note that: (i) the relative level of alternatively spliced pB1(WT) transcripts is higher in IGROV-1 than in HeLa, MCF-7 or HBL100 cells, and (ii) the predominant alternative splicing event of pB1(WT) in these cell lines is D10, whereas that of endogenous wild-type BRCA1 in blood related samples is D9,10 ( Fig. 4 and Supplementary Material, Figs 1 and 2 ).
transcripts. To be more precise, the combined genetic and splicing data lead us to formulate a D9,10 rescue model in which BRCA1 alleles with an associated D9,10 SF of %20-30% (as measured in blood related samples) confer tumor suppressor haplosufficiency (Fig. 4) . The actual value is probably closer to 20% than to 30% (according both to qPCR and dPCR estimations in Carrier 1, and to capillary electrophoresis estimations in Carriers 2-8), but at any rate is very similar to that observed in control samples. The finding that D9,10 is a predominant alternative splicing event not only in blood derived samples but also in clinically relevant tissues such as breast and ovary (Supplementary Material, Fig. S8 ) is critical to support our rescue model for both breast and ovarian cancer. Indeed, family history of breast and/or ovarian cancer is a key criterion for genetic testing for most participating ENIGMA and CIMBA sites, and segregation analysis modelled both breast and ovarian cancer risk, providing no indication that BRCA1 c.594-2A > C (IVS9-2A > C) could be associated with increased ovarian cancer risk only. Further, similar to our findings reported for breast cancer, case-control data from a parallel study by the Ovarian Cancer Association Consortium does not support an association with ovarian cancer risk, with BRCA1 c.594-2A > C identified in 2/ 16 121 cases and 4/26 167 controls (OCAC, unpublished data). Note that the BRCA1 D9,10 rescue model predicts lack of breast and ovarian cancer risk not only for BRCA1 variants causing exon 10 skipping (or exon 9 skipping), but to any loss-of-function mutation in exons 9 or 10 (nonsense or frame shift mutations), provided that the mutant allele produces normal levels of D9,10 transcripts (Fig. 4) . Evidently, the BRCA1 D9,10 rescue model presumes that D9,10 transcripts encode a protein isoform (BRCA1 p.Gly183_Lys223del ) that has tumor suppressor activity. To our knowledge, this BRCA1 isoform (lacking only 41 out of 1863 amino acid residues) has not been detected in vivo, nor functionally characterized in vitro, but tumor suppressor activity is fully compatible with structural considerations: 1) the 41 missing residues are unlikely to affect protein folding, since they are embedded in an intrinsically disordered protein region spanning amino acids 170-1649 (10); 2) BRCA1 Gly183_Lys223del includes all known functional domains/residues critical for tumor suppression, including the RING domain (spanning amino acids 2-103) that mediates binding to BARD1, an obligated heterodimer partner in vivo (11). Interestingly, BRCA1 p.Gly183_Lys223del lacks some residues critical for E3 ligase activity (12), a BRCA1 function that appears to be dispensable for tumor suppression (13, 14) . Yet, the most compelling argument supporting BRCA1 p.Gly183_Lys223del tumor suppressor activity stems from combined genetic and splicing analyses of BRCA1 c.591C > T (rs1799965). This variant, also not associated with the high risk of cancer expected for a pathogenic BRCA1 variant (current odds for causality of 8.50 Â 10 À 16 based on segregation and pathology information, ENIGMA unpublished data), expresses mostly D9,10 transcripts, a significant proportion of out-of-frame D9 transcripts, and very few FL transcripts (15) , strongly pointing to BRCA1 p.Gly183_Lys223del as a protein with tumor suppressor function. As far as we know, the only cancer predisposition gene for which a similar alternative splicing rescue model has been proposed is the tumor suppressor adenomatous poliposis coli (APC) gene, albeit in this case loss of function variants in the alternatively spliced region of APC exon 9 are not associated with lack of risk, but with a milder phenotype, termed attenuated familial adenomatous polyposis (16) . The BRCA1D9,10 rescue model highlights the often neglected relevance of naturally occurring alternative splicing in the clinical arena, and has obvious implications for variant classification algorithms. The ENIGMA consortium has developed and documented criteria for the five-tier classification of BRCA1/2 genetic variants based on qualitative and quantitative information (http://www.enigmaconsortium.org/, last accessed March 30, 2016). According to these rules, and consistent with those proposed by InSiGHT for Mismatch Repair gene variants (1), BRCA1/ 2 variants considered extremely likely to alter splicing based on position (typically IVS 6 1 or IVS 6 2) were initially all considered Class-4 (likely pathogenic) if untested for splicing alterations. However, the findings presented in this study have been pivotal to support amendment to these classification criteria, specifying need for particular caution in interpreting variants in instances where D9,10 (or other known naturally occurring inframe alternative splicing events) might rescue gene functionality (see Supplementary Material, Table S3 ). Hence, we also recommend caution in interpreting coding sequence variants that lead to premature termination codons in BRCA1 exons 9 and 10. This conservative stance is consistent with recent American College of Medical Genetics (ACMG) guidelines (17), which recommend considering the presence of alternative gene transcripts, understanding which are biologically relevant, and in which tissues the products are expressed. Thus, caution should be exercised when interpreting the impact of truncating variants confined to only a subset of transcripts, given the presence of other protein isoforms.
Of note, our results have additional implications unrelated to alternative splicing. More precisely, our study suggests that BRCA1 tumor suppressor activity tolerates a substantial reduction in expression level in vivo. Indeed, results shown in Figure 4 indicate that a BRCA1 allele producing as much as %70-80% of transcript encoding tumor suppressor deficient protein (as measured in blood-related samples) may not necessarily confer high-risk of developing cancer. This observation supports the conservative viewpoint of the ENIGMA consortium that, in the absence of other information, a variant can be considered pathogenic due to an effect on mRNA integrity if it only produces transcripts carrying a premature stop codon or an in-frame deletion disrupting known functional domain(s), as determined by semi-quantitative or quantitative methods.
In brief, there are several broad messages arising from the present study. Our results confirm that mRNA and genetic studies are warranted to inform the clinical significance of sequence alterations at the highly conserved intronic dinucleotides of splice donor and acceptor sites, and highlight the need to consider both variant haplotype and alternative splicing events in the design and interpretation of assays assessing the functional consequences of variants of uncertain clinical significance. We have also shown that comprehensive understanding of alternative splicing, paired with clinical genetic studies, is critical to understand the clinical consequences of complex splicing profiles observed for certain spliceogenic variants. Lastly, we provide a baseline hypothesis for future investigation and interpretation of other likely spliceogenic BRCA1/2 variants, a hypothesis that has implications for informing standards for generic variant classification guidelines.
Materials and methods
Genotyping and Sample Sets
We undertook screening of BRCA1 c.594-2A > C by direct genotyping, as part of the iCOGS experiment detailed elsewhere (18, 19) . This study included genotype and pathology results from breast cancer cases and controls participating in the (20)), we identified probands recruited through familial cancer clinics who were found to be positive for BRCA1 c.594-2A > C via clinical genetic testing. All study participants were enrolled into national or regional studies under ethically approved protocols.
Information was recorded for all variant carriers regarding cancer status, age at diagnosis/interview, breast tumor pathology (grade and ER, Progesterone Receptor (PR), and Herceptin-2 (HER2) Yet, some limitations should be highlighted. First, the model assumes (based on 36-cycle PCR capillary EP data) that D9,10SF in Controls and c.[594-2A > C; 641A > G] carriers is %29%, while other experiments suggests that the actual value is probably lower in both instances (Fig. 2, Supplementary Material, Fig. 2 ), albeit slightly increased in Carriers versus Controls. The model has been elaborated with data obtained in LCLs, not in clinically relevant tissues such as breast or ovarian. PTC, premature termination codon. status), and also pedigree and segregation information where available. For carriers identified though CIMBA and ENIGMA, the genotype for exonic variant c.641A > G (p.Asp214Gly) was sought from the original clinical testing report.
The BCAC dataset included 53 354 breast cancer cases and 49 720 controls and documented age at diagnosis/interview from 45 studies, detailed in (18) . The denominator reduced to 24 605 cases and 25 836 controls when including only invasive breast cancer cases and controls from the 11 studies with at least one observation (Supplementary Material, Table S1 ). These 11 studies included only individuals of European ancestry, and four (MCBS, MBCCSG, KARBAC, OFBCR) had undergone testing for germline BRCA1/2 pathogenic variants (4-100% of samples, depending on the BCAC study), including two of four studies which sampled cases on the basis of reported family history or presence of bilateral disease.
The CIMBA dataset included 11 105 female BRCA1 pathogenic variant carriers aged ! 18 years from 46 studies in CIMBA recruited through cancer genetics clinics. There were 4845 females without report of cancer, 4713 breast cancer cases, 933 ovarian cancer cases, and 614 individuals reporting both breast and ovarian cancer.
By contact with submitters and examination of clinical information, it was established that 11 of the 15 CIMBA probands overlapped with individuals included in the ENIGMA dataset, and one of proband was also a participant in BCAC site (Supplementary Material, Table S2 ). Only non-overlapping data was included in multifactorial likelihood analysis.
Statistical methods
We evaluated the effect of the BRCA1 c.594-2A > C variant on breast cancer risk in BCAC, using logistic regression models with adjustment for censoring age and population structure, based on six principal components which defined any residual population sub-structure. Censoring age was defined as age at breast cancer diagnosis, or age at last interview/follow-up. Only case-control studies in which the variant was observed at least once were included in the analysis.
In order to place case-control data into the same likelihood ratio (LR) framework as the other lines of evidence used for multifactorial likelihood analysis (21, 22) , we compared the likelihood of the distribution of BRCA1 c.594-2A > C variant carriers among cases and controls under the hypothesis that the variant has the same age-specific relative risks as the 'average' pathogenic BRCA1 mutation compared to that under the hypothesis that it is not associated with any increased breast cancer risk. Specifically, we used the age at diagnosis of cases and age at interview for controls together with the relative risks of breast cancer estimated from case series unselected for family history (6) to calculate the probability that each individual carrying BRCA1 c.594-2A > C in the sample is a BRCA1 pathogenic variant carrier given their affected status and age. Under the hypothesis that BRCA1 c.594-2A > C is a benign variant and does not confer increased breast cancer risk, we calculated the probability of the distribution of cases and controls among BRCA1 c.594-2A > C carriers as a simple binomial probability with p ¼ proportion of cases in the sample. These two likelihoods were then compared to derive the appropriate LR.
Bayes scores for segregation were derived as described previously (23) , and pathology LRs were applied as indicated in Spurdle et al. (24) The segregation scores, pathology LRs and casecontrol LRs are mutually independent and were combined to derive a combined odds for causality as described previously (21) .
We used the program Phase 2.0 (25) to estimate the most likely haplotypes of the BCAC cases and controls based on 29 variants in the region within and surrounding the BRCA1 locus, in order to examine if all c.594-2A > C variant carriers were observed on the same haplotypic background. Variants used for phasing were those submitted by ENIGMA for inclusion on the iCOGS chip design, the most common of which were rs8176258, rs1799967, rs1799950, rs4986852 and rs1799966.
mRNA analysis methods
Nomenclature
We use as reference sequences to describe BRCA1 genetic variants the GenBank reference sequences U14680.1 (cDNA) and NC_000017.11 (genomic). When referring to BRCA1 exons, we use exon numbering according to U14680.1. To characterize the BRCA1 alternative splicing landscape in c.[594-2A > C; 641A > G] carriers (sometimes referred throughout the text as variant allele carriers), we performed different RNA splicing analyses at the immediate vicinity of BRCA1 exon 10 (defined as the gene region spanning exons 8-11). Since our methodology do not allow analysis of complete transcripts (from 5 0 -end to poly(A) tail), we refer throughout the text to alternative splicing event containing transcripts, or alternative splicing events, rather than to alternative splicing transcripts or RNA isoforms (7) . For the very same reason, FL refers throughout the text to BRCA1 exons 9-and 10-containing transcripts (transcripts containing the exons9/10 junction defined in the GenBank reference sequenceU14680.1), and not necessarily to the complete 5711nt mRNA described in U14680.1. We have designated alternative splicing events by combining U14680.1 exon numbering with the following symbols: D (exon skipping), ᭢ (intron retention), p (proximal, or 5 0 ) and q (distal, or 3 0 ).
RNA analysis of human samples
Up to seven contributing laboratories (sites 1-7) performed RNA splicing analyses with various methodologies, including fluorescent RT-PCR followed by capillary electrophoresis, real-time qPCR, dPCR, Sanger sequencing and RNAseq (see Supplementary Material, Methods for further details). Experiments were performed in RNAs extracted from LCLs, short-term (3-6 days) cultured LEU or fresh peripheral blood. RNAs were derived from eight individual c.[594-2A > C; 641A > G] carriers (hereafter referred as Carriers 1-8) identified in four unrelated families from Australia (Carrier 1, LCL), Germany (Carrier 2, LCL), The Netherlands (Carriers 3-7, LEUs), and France (Carrier 8, peripheral blood) and healthy controls. We conducted several experiments designed to characterize the BRCA1 alternative splicing landscape observed in variant carriers. We used as quantitative description the SF, defined here as the contribution of individual alternative splicing events to the overall BRCA1 expression level (expressed as a percentage). As proxies for overall expression level, we used the R of all peak areas detected (capillary electrophoresis), or the signal obtained with a TaqMan assay recognizing the BRCA1 exons 23 and 24 junction (dPCR). The latter was selected since both BRCA1 exons 23 and 24 are likely constitutive exons (7) . Note that SF is a relative measure between signals arising from the same locus (in this case BRCA1), so that it is neither directly related to the actual expression level on individual splicing events, nor with the overall expression level from that locus. It is formally possible that increments in the SF of one particular alternative splicing event correlate with actual reductions in the expression level of that splicing event. For that reason, we determine the absolute expression level of individual alternative splicing events by qPCR with standard curves (see Supplementary Material, Methods for further details), and we performed relative expression analyses by dPCR, using as a reference a TaqMan assay recognizing the BRCA2 exons 26-27 junction. When indicated, we used as a positive control RNA extracted from LCLs carrying the BRCA1 variant c.591C > T [p.¼ (Cys197Cys)], known to increase D9 SF and D9,10 SF (15). Many experiments were performed in parallel with cultured cells treated/untreated with a nonsense mediated mRNA decay pathway (NMD) inhibitor, either Puromycin (Puroþ/À experiments) or Cycloheximide (Cycloþ/À experiments). RNA from Carrier 8 was directly extracted from fresh peripheral blood. Biallelic expression was assessed by alternative splicing event specific RT-PCR followed by Sanger sequencing through rs1060915 (an informative exonic SNP located at BRCA1 exon 13), using primers and protocols previously described (15) . In addition, we searched for BRCA1 tissue specific alternative splicing landscape in clinically relevant samples by comparing RNAs extracted from healthy control fresh peripheral blood, a pool of 10 healthy breast tissues (enriched normal epithelial areas selected by a pathologist) adjacent to breast tumor samples and commercial RNAs from healthy breast and ovarian human tissues. Experiments were performed by capillary electrophoresis of RT-PCR products, and by dPCR. Depending on the contributing laboratories, different RNA isolation and cDNA synthesis approaches were used (see Supplementary Material, Methods for further details). 
Minigene splicing assays
RNA interference experiments
To identify splicing regulatory proteins involved in BRCA1 exon 10 splicing, we performed a series of RNA interference experiments knocking down diverse splicing regulatory factors (hnRNPA1, Tra2b, SF2/ASF and SC35). Experiments were performed in the breast cancer cell line MDAMD231 (see Supplementary Material, Methods for further details).
Supplementary material
Supplementary Material is available at HMG online.
